Inventor · disambiguated record
Jared Gollob
Also filed as: GOLLOB JARED · GOLLOB JARED A
12 granted patents·9 pending applications·45 citations·filing 2009–2024
89Inventor score
Top patents by PatentIndex Score
21 records- 0193US12171768B2IRAK4 degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2022·Granted Dec 24, 2024·6 cites·4 claims
- 0290US8324368B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionGOLLOB JARED·Filed 2009·Granted Dec 4, 2012·12 cites·36 claims
- 0388US10246708B2Dosages and methods for delivering lipid formulated nucleic acid moleculesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Apr 2, 2019·16 cites·34 claims
- 0483US11806360B2Compositions and methods for treating transthyretin (TTR) mediated amyloidosisALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Nov 7, 2023·1 cites·27 claims
- 0582US8889644B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionGOLLOB JARED·Filed 2012·Granted Nov 18, 2014·5 cites·29 claims
- 0680US2024175024A1Dosages and methods for delivering lipid formulated nucleic acid moleculesALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0778US2024075052A1Compositions and methods for treating transthyretin (ttr) mediated amyloidosisALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0877US12031133B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 9, 2024·0 cites·16 claims
- 0977US9963700B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted May 8, 2018·1 cites·24 claims
- 1074US9339513B2Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genesGOLLOB JARED·Filed 2011·Granted May 17, 2016·4 cites·28 claims
- 1173US2025082645A1Irak4 degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1271US11827883B2Dosages and methods for delivering lipid formulated nucleic acid moleculesALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Nov 28, 2023·0 cites·40 claims
- 1371US10954516B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·0 cites·20 claims
- 1467US9566295B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 14, 2017·0 cites·25 claims
- 1567US2024309375A1Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disordersALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1664US2025019388A1Stat3 degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1761US2014336243A1Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 and VEGF GenesALNYLAM PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1857US2019284557A1Dosages and methods for delivering lipid formulated nucleic acid moleculesALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1953US2023277519A1Irak4 degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2052US8859516B2Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genesBUMCROT DAVID·Filed 2010·Granted Oct 14, 2014·0 cites·20 claims
- 2150US2023241075A1Irak degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jared Gollob files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →